Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. received an amended Schedule 13G filing (Amendment No. 7) from a Deerfield-affiliated investor group led by James E. Flynn. The filing reports that Deerfield Management Company, L.P., related Deerfield funds, Deerfield Partners, L.P., and James E. Flynn now beneficially own 0 shares of Nuvalent Class A common stock, representing 0.0% of the class.
All reporting persons state they have no sole or shared voting power and no sole or shared dispositive power over any Nuvalent shares, confirming ownership of 5 percent or less of the class. The Deerfield entities and Flynn file jointly pursuant to a joint filing agreement referenced in Exhibit A.
Deerfield-affiliated reporting persons for Nuvalent, Inc. disposed of all indirectly held Class A and Class B common stock, RSUs and stock options in connection with Nuvalent’s cash acquisition by GlaxoSmithKline. Each share was cancelled or tendered for $124.00 in cash, leaving all reported Nuvalent equity positions at zero.
Nuvalent, Inc. director Michael L. Meyers reported disposing of his Nuvalent equity in connection with its acquisition by GlaxoSmithKline affiliates. A tender offer purchased 5,146.0000 shares of Class A common stock at $124.00 per share, followed by a merger that made Nuvalent a wholly owned subsidiary of GlaxoSmithKline LLC.
In the same transaction, 3,444.0000 restricted stock units and multiple stock option grants covering 4,147.0000, 3,789.0000, 15,000.0000, 40,000.0000 and 8,361.0000 underlying shares were cancelled and converted into rights to receive cash based on the $124.00 offer price. The Form 4 shows 0.0000 holdings remaining in these reported securities after the transactions.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported transactions tied to the closing of a merger with a GlaxoSmithKline affiliate. She tendered 44,433 shares of Class A common stock for $124.00 per share in cash pursuant to a tender offer. In connection with the merger, 41,100 restricted stock units and multiple tranches of stock options were cancelled and converted into cash based on the $124.00 offer price and each option’s exercise price. Performance stock units totaling 14,350 shares, including 5,600 granted in 2025 and 8,750 granted in 2026, vested under the merger terms.
Nuvalent, Inc. director Sapna Srivastava reported dispositions of equity tied to the cash tender offer and merger with a GlaxoSmithKline affiliate. She tendered 5,146 shares of Class A Common Stock at $124.00 per share and had 3,444 restricted stock units plus several stock option grants cancelled and converted into cash rights under the Merger Agreement, leaving the reported positions in these securities at zero.
Nuvalent, Inc. director Christy J. Oliger reported disposing of equity awards in connection with the GlaxoSmithKline transaction. She tendered 1,324 Class A shares in the offer at $124.00 per share and had 6,091 time-based RSUs and 6,119 stock options canceled and converted into cash rights under the Merger Agreement, leaving no holdings in these awards.
Nuvalent, Inc. director Ron Squarer reported issuer dispositions of equity awards in connection with Nuvalent’s acquisition by a subsidiary of GlaxoSmithKline LLC. Following a $124.00-per-share cash tender offer and subsequent merger, 6,281 time-based restricted stock units and stock options for 4,418 shares at a $105.74 exercise price were canceled and converted into rights to receive cash, leaving no reported holdings of these awards.
Turner Christopher Durant, Chief Medical Officer of Nuvalent, Inc., reported multiple equity award and share dispositions tied to GlaxoSmithKline LLC’s acquisition of Nuvalent under a June 9, 2026 Agreement and Plan of Merger.
He tendered 31,530 Class A shares at $124.00 per share. In addition, 41,100 RSUs and 14,350 PSUs were cancelled and converted into cash based on the $124.00 offer price, and several stock option grants (including 144,200 options at $27.85 and 107,000 at $18.93) were cancelled for cash equal to the excess of the offer price over their exercise prices.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported merger-related equity transactions tied to a GlaxoSmithKline affiliate’s tender offer and subsequent merger. She tendered 17,017 shares of Class A Common Stock at $124.00 per share, while her restricted stock units, performance stock units and stock options were cancelled and converted into the right to receive cash based on the Offer Price under the Merger Agreement. A total of 14,350 performance stock units vested in connection with the merger, and the reported awards and options show zero remaining balances after these transactions.